Effect of early intravenous thrombolysis with an alteplase on the patients with acute cerebral infarction
10.3969/j.issn.1005-1678.2017.10.043
- VernacularTitle:阿替普酶早期静脉溶栓对急性期脑梗塞的疗效分析
- Author:
mei Qing LEI
1
;
fei Peng LIANG
Author Information
1. 山西省平遥县人民医院 神经内科
- Keywords:
rt-PA;
acute Cerebral Infarction;
sodium ozagrel;
thrombolytic therapy
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(10):107-108,111
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of of rt-Pa Early Thrombolytic Therapy on the Patients with Acute Cerebral Infarction (ACI). Methods 40 patients with acute cerebral infarction were randomly divided into rt-PA group and control group, 20 cases in each group. The treatment time window was less than 3 hours. On the basis of the routine medication of cerebral infarction, rt-PA group was given rt-PA intravenous thrombolytic therapy, the control group was treated with sodium ozagrel. The National Institutes of Health Stroke Scale (NIHSS) and Barthel index (BI) were used to evaluate the efficacy and safety. Results The NIHSS scores of two groups after treatment were significantly improved compared with before treatment, rt-PA group improved significantly better than the control group (P<0.05); At 21 days of treatment, the excellence rate of rt-PA group was 80% and the ratio of BI≥95 was 40.00%, the excellence rate of control group was 25.0% and the ratio of BI≥95 was 20.00%, the rt-PA group was significantly higher than the control Group (P<0.01); there was no significant difference between the two groups in the mortality rate, the incidence of secondary cerebral hemorrhage and vascular restenosis in the two groups. Conclusion Within 3 hours of onset of ACI, compared with the sodium ozagrel therapy, the rt-PA intravenous thrombolytic therapy is more safe and effective in the treatment of ACI patients, and it is worthy to be widely used in clinical treatment.
